The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, briefly discusses the results of the SWOG S1826 trial (NCT03907488), which is comparing nivolumab-AVD (N-AVD) versus brentuximab vedotin-AVD (BV-AVD) in patients with advanced stage classical Hodgkin lymphoma (cHL). Prof. Borchmann comments on the promising results demonstrated so far, although longer-term follow-up is required. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
